Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience

Naseema Gangat; Kristen McCullough; Aref Al-Kali; Kebede H. Begna; Mrinal M. Patnaik; Mark R. Litzow; William Hogan; Mithun Shah; Hassan Alkhateeb; Abhishek Mangaonkar; James M. Foran; Jeanne M. Palmer; Animesh Pardanani; Ayalew Tefferi

doi:10.1111/bjh.18284

Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience

Naseema Gangat, Kristen McCullough, Aref Al-Kali, Kebede H. Begna, Mrinal M. Patnaik, Mark R. Litzow, William Hogan, Mithun Shah, Hassan Alkhateeb, Abhishek Mangaonkar, James M. Foran, Jeanne M. Palmer, Animesh Pardanani, Ayalew Tefferi

Research output: Contribution to journal › Letter › peer-review

Original language	English (US)
Pages (from-to)	e54-e58
Journal	British journal of haematology
Volume	198
Issue number	4
DOIs	https://doi.org/10.1111/bjh.18284
State	Published - Aug 2022

Keywords

fedratinib
myelofibrosis
ruxolitinib

ASJC Scopus subject areas

Hematology

Access to Document

10.1111/bjh.18284

Cite this

Gangat, N., McCullough, K., Al-Kali, A., Begna, K. H., Patnaik, M. M., Litzow, M. R., Hogan, W., Shah, M., Alkhateeb, H., Mangaonkar, A., Foran, J. M., Palmer, J. M., Pardanani, A., & Tefferi, A. (2022). Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience. British journal of haematology, 198(4), e54-e58. https://doi.org/10.1111/bjh.18284

Gangat, N, McCullough, K, Al-Kali, A, Begna, KH , Patnaik, MM , Litzow, MR , Hogan, W, Shah, M, Alkhateeb, H, Mangaonkar, A, Foran, JM , Palmer, JM , Pardanani, A & Tefferi, A 2022, 'Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience', British journal of haematology, vol. 198, no. 4, pp. e54-e58. https://doi.org/10.1111/bjh.18284

@article{1e501fb5db4a46b8bdbd14221327268c,

title = "Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience",

keywords = "fedratinib, myelofibrosis, ruxolitinib",

author = "Naseema Gangat and Kristen McCullough and Aref Al-Kali and Begna, {Kebede H.} and Patnaik, {Mrinal M.} and Litzow, {Mark R.} and William Hogan and Mithun Shah and Hassan Alkhateeb and Abhishek Mangaonkar and Foran, {James M.} and Palmer, {Jeanne M.} and Animesh Pardanani and Ayalew Tefferi",

year = "2022",

month = aug,

doi = "10.1111/bjh.18284",

language = "English (US)",

volume = "198",

pages = "e54--e58",

journal = "British journal of haematology",

issn = "0007-1048",

publisher = "Wiley-Blackwell",

number = "4",

}

TY - JOUR

T1 - Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher

T2 - A real-world experience

AU - Gangat, Naseema

AU - McCullough, Kristen

AU - Al-Kali, Aref

AU - Begna, Kebede H.

AU - Patnaik, Mrinal M.

AU - Litzow, Mark R.

AU - Hogan, William

AU - Shah, Mithun

AU - Alkhateeb, Hassan

AU - Mangaonkar, Abhishek

AU - Foran, James M.

AU - Palmer, Jeanne M.

AU - Pardanani, Animesh

AU - Tefferi, Ayalew

PY - 2022/8

Y1 - 2022/8

KW - fedratinib

KW - myelofibrosis

KW - ruxolitinib

UR - http://www.scopus.com/inward/record.url?scp=85130558234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85130558234&partnerID=8YFLogxK

U2 - 10.1111/bjh.18284

DO - 10.1111/bjh.18284

M3 - Letter

C2 - 35614565

AN - SCOPUS:85130558234

SN - 0007-1048

VL - 198

SP - e54-e58

JO - British journal of haematology

JF - British journal of haematology

IS - 4

ER -

Limited activity of fedratinib in myelofibrosis patients relapsed/refractory to ruxolitinib 20 mg twice daily or higher: A real-world experience

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this